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Abstract
Currently, the treatment for ovarian cancer entails cytoreductive surgery followed by chemotherapy, mainly, carboplatin
combined with paclitaxel. Although this regimen is initially effective in a high percentage of cases, unfortunately within few
months of initial treatment, tumor relapse occurs because of platinum-resistance. This is attributed to chemo-resistance of
cancer stem cells (CSCs). Herein we show for the first time that withaferin A (WFA), a bioactive compound isolated from the
plant Withania somnifera, when used alone or in combination with cisplatin (CIS) targets putative CSCs. Treatment of nude
mice bearing orthotopic ovarian tumors generated by injecting human ovarian epithelial cancer cell line (A2780) with WFA
and cisplatin (WFA) alone or in combination resulted in a 70 to 80% reduction in tumor growth and complete inhibition of
metastasis to other organs compared to untreated controls. Histochemical and Western blot analysis of the tumors revealed
that inclusion of WFA (2 mg/kg) resulted in a highly significant elimination of cells expressing CSC markers - CD44, CD24,
CD34, CD117 and Oct4 and downregulation of Notch1, Hes1 and Hey1 genes. In contrast treatment of mice with CIS alone
(6 mg/kg) had opposite effect on those cells. Increase in cells expressing CSC markers and Notch1 signaling pathway in
tumors exposed to CIS may explain recurrence of cancer in patients treated with carboplatin and paclitaxel. Since, WFA
alone or in combination with CIS eliminates putative CSCs, we conclude that WFA in combination with CIS may present
more efficacious therapy for ovarian cancer.
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Introduction
Epithelial ovarian cancer (EOC) remains the leading cause of
death in women among gynecologic cancers and is the 5th highest
cause of cancer-related deaths in women in the United States
[1,2]. The majority of ovarian cancers are diagnosed at advanced
stage due to the mainly non-specific symptoms. Currently, the
treatment for ovarian cancer entails cytoreductive surgery followed
by chemotherapy, employing mainly platinum/taxane combina-
tion [3]. Although this regimen is initially effective in a high
percentage of cases (70 to 80%), unfortunately 70% of women
develop recurrent cancer within few months of initial treatment as
a result of platinum-resistance [4,5]. In addition, cisplatin (CIS) is
associated with multiple severe side effects such as nausea,
vomiting, myelosuppression, hepatotoxicity, neurotoxicity, neph-
rotoxicity and ototoxicity [4,6–9]. Therefore, need for new
treatment options that target cancer cells and in particular
putative cancer stem cells is mandatory either at first-line setting
or even more at the first- and second-line management of
recurrent ovarian cancer.
In our previous studies [10], we showed for a first time that
withaferin A (WFA), a bioactive compound isolated from the plant
Withania somnifera, when used alone or in combination with CIS
had a time- and dose-dependent synergistic effect on inhibition of
cell proliferation and induction of cell death, thus reducing
required dosage of cisplatin. We also showed that while WFA
achieves its antitumor effect through generation of ROS leading to
DNA damage, CIS achieves its effects though direct binding to
DNA causing the formation of DNA adducts. Combination
treatment also resulted in a significant enhancement of reactive
oxygen species (ROS) production and DNA damage.
WFA has been a part of Indian traditional medicine for
centuries. It is available in US over-the-counter as a dietary
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supplement and is known to treat various disorders due to its anti-
inflammatory [11,12], anti-bacterial [13], and cardio protective
properties [14]. In recent years, WFA has been suggested as a
potential anti-cancer compound shown to prevent tumor growth,
angiogenesis, and metastasis [15,16] in various types of cancer
[17–26]. Mechanisms by which WFA attains its anticancer activity
include inactivation of Akt and NF-kB [27] to achieve apoptosis,
decrease in pro-survival protein Bcl-2 [28], G2/M cell cycle arrest
[29,30], generation of reactive oxygen species (ROS) [31,32],
induction of Par-4 [17], activation of caspase 3 and 9 activities,
DNA damage [10], inhibition of HSP90 [20], regulation of
FOXO3a and Bim [15] inhibition of Notch-1 [33] and down
regulation of expression of HPV E6 and E7 oncoproteins [19].
Development of drug resistance and recurrence of ovarian
cancer has been a major clinical problem. A number of
mechanisms that induce drug resistance have been proposed.
Over the last several years, there has been increasing evidence that
‘‘cancer stem cells (CSCs)’’, are the most important trigger of
tumor progression, chemo-resistance and relapse after initial
treatment [34,35]. First evidence for the existence of cancer stem
cells came in the year 1997, with the identification of leukemia
stem cells [36,37]. In the year 2003, Al-Hajj et al. [38]
experimentally demonstrated the hierarchical stem cell origin in
breast cancer. However, until recently the existence of putative
cancer stem cells within solid tumors had remained controversial
[39]. In recent studies using murine models for brain, skin and
intestinal tumors, three independent groups have provided
convincing evidence for the existence of CSCs in tumors and
their role in tumor expansion [40–42]. Accordingly, CSCs within
tumor mass undergo self-renewal and give rise to heterogeneous
cancer lineages that comprise tumor tissue. CSCs purified
accordingly to some surface markers are able to form tumors
when injected into nude mice [36,43,44]. Since, ovarian cancer is
very heterogeneous; different cell surface markers have been
reported for putative ovarian CSCs. Most commonly reported
include CD24, CD34, CD44, CD133, CD117, ALDH1, Oct4,
MyD88 and EpCAM [45–53]. Since, CSCs are considered to be
major players responsible for developing drug resistance and
hence leading to cancer recurrence [52,53], targeting CSCs and
inhibiting their self-renewal will lead to reduction of cancer growth
[33].
In our current study, we show for the first time that WFA alone
or in combination with CIS if employed to treat mice bearing
human orthotopic ovarian tumors not only suppresses tumor
growth but targets cells expressing CSC markers as well as inhibits
Notch1 and its downstream signaling genes (Hes1 and Hey1) that
have been reported to play a crucial role in self-renewal and
maintenance of CSCs (33).
Material and Methods
Cell line and cell culture
Ovarian epithelial cancer cell line A2780 was initially obtained
from Denise Connolly (Fox Chase Cancer Center) and was
maintained in RPMI 1640 medium containing insulin and
supplemented with penicillin/streptomycin (100 IU/ml and
100 mg/ml) and 10% fetal bovine serum (FCS) (Hyclone, Atlanta,
GA) as described previously [10].
Cell migration Boyden chamber assays
Cell migration in vitro was assayed by determining the ability of
cells to migrate through a synthetic basement membrane. The
procedure used was as described previously [54]. Briefly,
polycarbonate filters (8 mM) were placed in modified Boyden
chamber. A2780 cells in log phase were trypsinized and plated in 6
wells plates. After 24 h of plating, cells were treated with WFA and
CIS both alone and in combination as described previously [10].
After 24 h of treatment, cells were trypsinized and suspended in
serum free medium. A total of 26105 cells were transferred to the
top chamber. The medium containing 5% FBS was added to the
lower chamber. The cells were incubated at 37uC for 24 h and
allowed to migrate through the membrane. Non-migrated cells
were removed with a clean cotton swab. Migrated cells on other
side of the membrane were stained with crystal violet and counted
in three different fields under Olympus microscope. The
experiments were repeated for three times. The values represented
are the mean 6 SEM of three independent experiments.
Generation of orthotopic ovarian tumors in nude mice
and treatment with WFA and CIS both alone and in
combination
Orthotopic ovarian tumors were generated by injecting ovarian
cancer cell line A2780 directly into ovary as described by Nunez
Cruz et al. [55]. Briefly, A2780 (16106) cells were directly injected
into left ovary of 5 to 6 weeks old nu/nu female mice (Jackson
Laboratory) under aseptic conditions and under light anesthesia.
After 10 days of post-cell injection, mice were treated with 1)
vehicle control (10% DMSO and 90% glyceryl trioctanoate), 2)
WFA 2 mg/kg, 3), CIS 6 mg/kg, and 4) WFA 2 mg/kg plus CIS
6 mg/kg. Five animals randomly were included in each group.
CIS in saline was injected i.p. once a week, whereas WFA was
injected i.p. every other day. After 4 weeks of treatment, animals
were sacrificed; tumor and other tissues such as un-injected ovary,
lung, kidney, liver, adrenal and heart were collected from each
mouse. Tumors were weighted at the time of collection. The
tumors and other tissues were divided into two parts, one part was
snap frozen, and second part was fixed in 10% buffered formalin.
The animals’ experiments were approved by the University of
Louisville, Institutional Animal Care and Use Committee
(IACUC) (protocol # 12063).
Formalin fixed tumor and tissues were processed and embedded
in paraffin using standard protocols as described previously [56].
Five mM thick sections of the embedded tumors and tissues were
prepared and stained with Hematoxylin and Eosin (H&E).
Sections in triplicates were examined under microscope and
photographed. Histopatholoigcal analysis of sections was per-
formed by a trained pathologist Dr. Mana Moghadamfalahi.
Immunohistochemistry
Formalin fixed paraffin embedded tissues were deparaffinized in
xylene and rehydrated in a decreasing graded series of ethanol as
described previously [56]. Sections were heated at 95uC in 10 mM
sodium citrate (pH 6.0) for 20 min, cooled to room temperature
and then rinsed in PBS. Sections were incubated with 0.3%
hydrogen peroxide in methanol for 10 min at room temperature
to quench endogenous peroxidase followed by two rinses in PBS
(5 min each), and were blocked with normal goat serum using
reagents from ABC kit from Vector Laboratories for 60 min at
room temperature following the instructions from the supplier.
The blocking solution was removed by draining and sections were
incubated with specific antibody with appropriate dilution
according to instructions from the suppliers at 4uC for overnight
in a humidified chamber. The antibodies for CD24 (cat #
SAB14202713), CD44 (cat # SAB1405590), CD117 (cat #
SAB4300489) and Oct4 (cat # P0873) were obtained from Sigma-
Aldrich, and antibody for CD34 (cat # sc-19587) was obtained
from Santa Cruz Biotechnology. After rinsing the sections three
WFA and Cisplatin Target Ovarian Cancer Stem Cells
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times (5 min each) with PBS, sections were incubated with
biotinylated anti-rabbit (for polyclonal antibodies) or anti-mouse
(for monoclonal antibodies) from the ABC kits (Vector Labora-
tories) at room temperature for 45 min followed by incubation
with streptavidin. After three rinses (5 min each) with PBS,
sections were incubated with 3,39-diaminobenzidine (DAB, Sigma)
to develop color. The sections were examined under Nikon Elipse
E400 microscope and photographed.
Protein isolation and western blot analysis
A2780 cells were plated into 6 well plates. After 24 h of plating,
cells were treated with WFA and CIS both alone and in
combination as described previously (10). After 48 h of treatment,
cells were lysed in chilled lysis buffer [50 mM Tris-HCl (pH 7.5),
150 mM NaCl, 0.1% NP-40, 1 mM Na3VO4, and 1 mM NaF)
supplemented with Complete Mini Protease Inhibitor tablet
(Roche Molecular Biochemicals, Indianapolis, IN). To prepare
extract from normal and tumor tissues, tissues were suspended in
lysis buffer and homogenized on ice using Polytron homogenizer
followed by centrifugation at 10,000 rpm for 5 min. The
supernatants were collected and protein concentration in each
sample was determined using Bradford method (BioRad Labora-
tories) according to supplier’s instructions. Forty mg of protein
from each sample was fractionated on SDS-polyacrylamide gels
and transferred to nitrocellulose membranes as described previ-
ously [56]. Blocking of nonspecific proteins was performed by
incubation of the membranes with 5% nonfat dry milk in Tris
buffered saline Tween-20 (TBST) for 1 h at room temperature.
The membranes were incubated with specific antibody with
appropriate dilution as suggested by the suppliers. Antibody for
Notch 1 (cat # N6786), Hey1 (cat # SAB1404975) and b-actin
(cat # A3854) were obtained from Sigma-Aldrich, and antibody
for Hes1 (cat # sc-165996) was obtained from Santa Cruz
Biotechnology. The membranes were washed three times (5 min
each) with TBST, followed by incubation with horseradish
peroxidase conjugated secondary antibody (1:5,000 dilution) in
TBST. The membranes were rinsed three times (5 min each) with
TBST and the immuno-reactive bands were visualized by
enhanced chemiluminescence. Membranes were stripped off for
10 min with methanol containing 3% H2O2 and probed with b-
actin antibody in order to serve as an internal control.
Statistical analysis
Statistical comparison of data was carried out by the student’s t
test (for single comparison). Probability of p,0.05 determined
from the two-sided test was considered significant. The statistical
analysis was carried out by using SPSS 10.0 software.
Results
WFA/CIS combination inhibits cell migration in vitro
Various steps are involved in tumor progression and metastasis
including detachment of tumor cells from the primary tumor site,
transmigration into lymph- or blood vessels, attachment to
endothelium at distant sites of metastasis followed by seeding into
new location and subsequent expansion. To examine the effect of
WFA and CIS on A2780 cell migration, we treated the A2780 cells
with WFA and CIS both alone and in combination for 48 h. As
shown in Fig. 1, by employing Boyden chambers we noticed that
the treatment of cells with WFA or CIS alone inhibited cell
migration in a dose-dependent manner as compared to untreated
control cells. While treatment of cells with 20 mM CIS inhibited
cell migration, addition of WFA (0.5 mM or 1.5 mM) to CIS
resulted in enhanced inhibition of cell migration, suggesting that
WFA combined with CIS is more effective than each agent
employed.
WFA/CIS combination suppresses tumor growth and
metastasis in nude mice
In our in vitro studies, we showed that treatment of CIS-
sensitive cell lines (A2780 and CaOV3) as well as CIS-resistance
cell line (A2780/CP70) with WFA and CIS both alone and in
combination inhibited cell proliferation in a time- and dose-
dependent manner and induced cell apoptosis and DNA damage.
Moreover, the combined effect of WFA and CIS was synergistic
[10]. To assess the efficacy of WFA/CIS combination on tumor
growth and metastasis in vivo, we tested the effect of WFA and
CIS both alone and in combination on tumor growth and
metastasis in nude mice bearing inoculated orthotopic human
ovarian tumors. Murine orthotopic tumors were established by
injecting A2780 cells directly into left ovary of 5 to 6 week old nu/
nu female mice. Beginning from day 10 after inoculation of tumor
cells, animals were treated with WFA and CIS both alone and in
Figure 1. Effect of WFA and CIS both alone and in combination
on cell migration. A2780 cells were treated with different concen-
tration of WFA and CIS both alone and in combination for 48 h. The
cells were trypsinized and subjected for cell migration using Boyden
chamber. Cells were stained with crystal violet and photographed (A).
The stained cells were counted under microscope using three different
areas; values shown are mean 6 SD of three independent experiments.
* Represents significant compared to control at p#0.05 (B). Con =
control, W = WFA. Values shown in parenthesis are mM.
doi:10.1371/journal.pone.0107596.g001
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combination as detailed in Materials and Methods section. After 4
weeks of treatment, animals were sacrificed. We noticed that the
control mock-treated animals developed highly vascularized and
large tumors (Fig. 2). At the same time 4 out of 5 WFA (2 mg/kg)
alone-treated animals developed tumors that were significantly
smaller in size. Similarly, 3 out of 5 animals treated with CIS
(6 mg/kg) developed tumors that were significantly smaller in size
as compared to mock-treated controls. Moreover, treatment of
animals with WFA (2 mg/kg) in combination with CIS (6 mg/kg)
resulted in 70 to 80% reduction in tumor weight compared to
untreated control animals (Fig. 2) and out of 5 mice, only three
mice developed tumors. No significant differences in tumor weight
were observed in mice treated with WFA and CIS alone or in
combination (Fig 2).
H&E histo-pathological analysis of un-injected opposite ovaries,
livers, and lungs showed metastasis to livers and ovaries in mock-
treated animals only. Metastatic cells comprised ,10% of cells in
those organs (Fig. 3). In contrast no metastases were observed in
WFA and CIS treated groups. These results suggest that
combination of low dose of WFA (2 mg/kg) with suboptimal dose
of CIS (6 mg/kg) is highly effective in suppressing tumor growth
and metastasis of orthotopic ovarian tumors in nude mice. This
indicates that it would be possible to reduce therapeutic dose of
CIS when combined with WFA in humans to ameliorate side
effects associated with high dosage of CIS.
WFA alone or in combination with CIS eliminates
putative cancer stem cells in orthotopic ovarian tumors
Chemo-resistance and recurrence of ovarian cancer is a major
problem and cause of death. In recent years, a concept of CSCs in
solid cancers including ovarian cancers has been proposed [57,58].
CSCs have been reported to be responsible for chemo-resistance,
tumor growth and recurrence of cancer after treatment. Putative
CSCs have been reported as cancer initiating cells capable to
develop tumors when injected into nude mice [57]. To test if WFA
when used alone or in combination with CIS targets CSCs, we
performed immunohistochemical analysis of the tumors collected
from the mock-treated animals and animals treated with WFA and
CIS both alone and in combination using the antibodies for
markers expressed by putative CSCs including CD44, CD24,
CD34, CD117 and Oct4 [56]. As shown in Figs. 4–6, we observed
,10–20% of cells positive for CD44, CD24, CD34, CD117 and
Oct4 in tumors collected from untreated animals. However,
treatment of animals with WFA (2 mg/kg) resulted in a highly
significant reduction in number of those cells. In contrast,
treatment of animals with CIS alone at a dose of 6 mg/kg
resulted in significant increase in CD44, CD24, CD34, CD117
and Oct 4 positive cells (60%) (Figs. 4–6). More importantly,
treatment of animals with WFA in combination with CIS (6 mg/
kg) significantly reduced number of cells expressing CSC markers.
Figure 2. Effect of WFA and CIS treatment on tumor growth. A: 16106 A2780 cells were injected into female mouse ovary. After 10 days of
post-injection, mice were treated with WFA and CIS both alone or in combination for four weeks. Mice were sacrificed; tumors were excised out,
photographed and weighted. Tumors shown are representative from each group. B: Tumors weight was plotted from each group. Horizontal line
represents median weight of each group. Treated group showed significantly lower weight than untreated mice. Results are mean (red line) and 6
SD (vertical bar). * Represents significant compared to control at p#0.05.
doi:10.1371/journal.pone.0107596.g002
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WFA alone or in combination with CIS down regulates
the expression of CSC-related markers
To confirm our immuno-histochemical analysis of CD44,
CD24, CD34, CD117 and Oct4 positive cells in orthotopic
tumors, we performed Western blot analysis of the tumor extracts
using specific antibody for markers detected by immuno-
histochemical staining. As shown in Fig. 7, expression of CD24,
CD34, CD44, and Oct4 antigens was significantly down-regulated
in tumors collected from animals treated with WFA alone as
compared to tumors from mock-treated animals. In contrast a
significant increase in expression of CD24, CD34, CD44 and Oct4
was observed in tumor extracts from animals treated with CIS
(6 mg/kg) as compared to mock-treated mice or mice treated with
WFA (2 mg/kg) alone. Interestingly, treatment of animals with
WFA (2 mg/kg) in combination with CIS (6 mg/kg) resulted in a
significant elimination of cells expressing CD44, CD24, CD34 and
Oct4 antigens.
Increase in number of cells expressing markers of putative CSCs
in tumors collected from animals treated with CIS as analyzed by
immuno-staining as well as Western blot analysis suggests that
treatment by CIS may increase number of cells expressing these
markers and may explain development of chemo-resistance and
reoccurrence of ovarian cancer in patients treated with CIS or its
derivative such as carboplatin in combination with paclitaxel that
are commonly used in chemotherapy. In contrast elimination of
cells expressing CSC markers in tumors on treatment with WFA
alone or in combination with CIS (6 mg/kg) demonstrates that
WFA is highly effective in eliminating cells expressing CSC
markers.
WFA alone or in combination with CIS inhibits Notch 1
and its downstream signaling genes (Hes1 and Hey1)
Self-renewal, drug resistance and differentiation are key
characteristics of CSCs. Sonic Hedgehog (Shh), Notch1, Twist1,
Snail and Wnt1 signaling transduction pathways play major roles
in the self-renewal of these cells [33,59–68]. WFA has been
reported to inhibit Notch-1 and downstream signaling genes (Hes1
and Hey1) [33,68]. Notch 1 signaling pathway is associated with
regulation of cell fate at several distinct developmental stages and
has been implicated in cancer initiation and progression
[63,69,70]. In our present study as shown in Fig. 8, we noticed
highly significant inhibition of expression of Notch 1 and its
downstream signaling genes Hes1 and Hey1 in tumors collected
from mice treated with WFA (2 mg/kg) as compared to tumors
from control mock-treated animals. In contrast, animals treated
with CIS (6 mg/kg) showed a highly significant increase in levels
of Notch1, Hes1 and Hey1 genes. What is important, tumors
collected from mice treated with WFA (2 mg/kg) in combination
with CIS (6 mg/kg) showed significant decreased levels of Notch1
as well as Hes1 and Hey1 proteins (Fig. 8), suggesting downreg-
ulation of Notch1 signaling by WFA alone or in combination with
CIS leading to elimination of putative CSCs.
Figure 3. Effect of WFA and CIS both alone and in combination
on tumor metastasis. Mice were treated with WFA and CIS as
indicated in Figure 2. Tumors and other tissues sections were stained
with H&E and examined by a trained pathologist. Metastasis (shown by
arrows) was observed in un-injected ovaries and livers and represent
approximate 10% of the cells.
doi:10.1371/journal.pone.0107596.g003
Figure 4. Immunohistochemical analysis of CD44 and CD34 positive cells in tumors collected from mock treated mice (control) and
mice treated with WFA and CIS both alone and in combination. The data shown is representative of two independent experiments. W =
WFA. Values shown in parenthesis are mg/kg.
doi:10.1371/journal.pone.0107596.g004
WFA and Cisplatin Target Ovarian Cancer Stem Cells
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Discussion
The most common first line chemotherapy used for ovarian
cancer after cytoreductive surgery is carboplatin in combination
with paclitaxel. Initial response rate to this combination is very
high (70 to 80%), however within 6 to 20 months after initial
treatment tumor relapse and patients become resistance to CIS
[71]. Resistance to CIS has been associated with number of
mechanisms such as increase in glutathione and metallothionein
levels, decrease in drug uptake, increase in DNA repair
mechanisms (due to enhanced expression of excision repair genes)
and tolerance of the formation of platinum-DNA adducts [72].
Change in status of p53 has also been reported to play important
role in sensitivity of CIS [73,74].
In recent years, several investigators have reported a presence of
small population of CSCs in tumor tissues to be responsible for
induction of chemo-resistance and recurrence of cancer [75–77].
The convincing evidence for the role of CSCs in ovarian cancer
was provided by Bapat et al. [45] who showed the presence of
CSCs at single cell level in the ascites of an ovarian cancer patient,
that could sequentially propagate tumor over several generations.
Consistent with this, many other investigators reported the
presence of CSCs in ovarian cancer cell lines, patients’ ovarian
tumors and tumor associated-ascites [57,76,77]. As a follow up of
these observations CSCs have been isolated based on the presence
of some extracellular markers. Most common makers used for
ovarian CSCs include CD44, CD24, CD34, CD117 and CD133.
CSCs also express ALDH1, Oct4, Myd88 and EpCAM
[47,51,57,60,78,79]. An increase in number of CSCs in ovarian
tumors correlates with a poor prognosis, including shorter overall
and disease free survival [80–82]. Development of chemo-
resistance of ovarian cancer could be explained by enrichment
for CSCs [77,83–85]. In a recent study, Abubaker et al. [53]
demonstrated using two ovarian cancer cell lines (epithelial
OVCA433 and mesenchymal HEY) enrichment for a population
of cells with high expression of CSC markers at the protein as well
as mRNA levels after treatment with CIS, paclitaxel and the
combination of both. In addition, these investigators showed
Figure 5. Immunohistochemical analysis of CD24 and CD117 positive cells in tumors collected from mock treated mice (control)
and mice treated with WFA and CIS both alone and in combination. The data shown is representative of two independent experiments. W
= WFA. Values shown in parenthesis are mg/kg.
doi:10.1371/journal.pone.0107596.g005
Figure 6. Immunohistochemical analysis of Oct4 positive cells
in tumors collected from mock treated mice (control) and mice
treated with WFA and CIS both alone and in combination. The
data shown is representative of two independent experiments. W =
WFA. Values shown in parenthesis are mg/kg.
doi:10.1371/journal.pone.0107596.g006
Figure 7. Western lot analysis of CD24, CD34, CD44, and Oct4
proteins from tumors collected from mock treated mice and
mice treated with WFA and CIS both alone and in combination.
Beta-actin was used as an internal control. The data shown is
representative of two independent experiments. Con = control, W =
WFA. Values shown in parenthesis are mg/kg.
doi:10.1371/journal.pone.0107596.g007
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increase in tumorigenic properties of ovarian cancer cells in
response to chemotherapy drugs. In the present study, we show
somehow in agreement with those studies [53] that the number of
CSCs increases in animals bearing orthotopic ovarian tumors
treated with CIS at 6 mg/kg. This increase in CSCs population in
ovarian tumors of mice with CIS may explain the development of
chemo-resistance and reoccurrence of ovarian cancer in patients
treated with CIS or its derivative carboplatin employed in
combination with paclitaxel.
Increase in number of CSCs in tumors inoculated in nude mice
followed by CIS treatment is result of amplification of CSCs
present in human cancer cell line A2780. On other hand growing
tumor will attract host-derived normal stem cells that will provide
stroma and vasculature for expanding tumor tissue. These cells
could provide trophic signals for CSCs, and this is currently
investigated in our laboratories.
In the past years a great deal of efforts has been devoted to
develop drugs that can kill cancer cells as well as CSCs in order to
reduce chemo-resistance and recurrence of cancer after treatment.
WFA as reported exhibits an inhibitory effect against several
different types of cancer cells. However, its effect on CSCs has not
been explored so far. In our previous study [10], we demonstrated
that WFA when used alone or in combination with CIS inhibits
cell proliferation and induce cell death of both CIS-sensitive
(A2780 and CaOV3) as well as CIS-resistant (A2780/CP70) cell
lines. In our present follow-up study we show that WFA (2 mg/kg)
when used alone or in combination with CIS to treat mice bearing
orthotopic ovarian tumor reduced tumor growth by 70 to 80%
and prevented metastasis to other organs. In addition, treatment of
mice bearing orthotopic ovarian tumors with WFA alone or WFA
+ CIS eliminated cells that express CSC markers. (CD44, CD24,
CD34, CD117 and Oct4). In contrast the number of these cells as
mentioned above increased in our hands after treatment by CIS
alone. Thus, our results clearly demonstrate that combination of
low dose of WFA (2 mg/kg) with suboptimal dose of CIS (6 mg/
kg) is highly effective in suppressing the tumor growth and
elimination of putative CSCs ‘‘expanded’’ by CIS treatment.
Since, therapeutic dose of CIS is 8 mg/kg [19], WFA in
combination with CIS has potential to be highly effective and
efficacious therapy for ovarian cancer and may ameliorate CIS-
therapy related side effects.
Self-renewal, drug resistance and differentiation are key
characteristics of CSCs and several developmental pathways such
as Sonic Hedgehog (Shh), Notch, Wnt and TGFb, Twist, and
Snail which have been shown to be crucial in these processes
[33,59–67,86]. WFA has been reported to inhibit Notch1 and
downstream signaling genes (Hes1 and Hey1) [43,77] that have
been implicated in cancer initiation and progression [63,69,70].
In our present study, we show for a first time highly significant
inhibition of Notch1 and its downstream signaling proteins Hes1
and Hey1 in tumors collected from animals treated with WFA
(2 mg/kg) as compared to tumors from mock-treated animals. In
contrast, animals treated with CIS (6 mg/kg) alone showed a
significant increase in levels of Notch1, Hes1 and Hey1 genes
which is consistent with the increase in number of CSCs,
suggesting an important role of Notch1 transduction pathway in
amplification of those cells. More importantly, treatment of
animals with WFA (2 mg/kg) + CIS (6 mg/kg) prevented increase
of Notch1, Hes1 and Hey1 expression, suggests that such
combined therapy ameliorates unwanted effect of CIS treatment
alone and unwanted expansion of CSCs. Thus, treatment of
patients that have become resistance to CIS and have developed
recurrence cancer could be benefited by WFA treatment alone or
in combination with CIS.
Conclusions
The silent observation from this study is that treatment of mice
bearing human ovarian tumors with CIS results in an unwanted
expansion of cells that express CSC markers, what may lead to
CIS resistance and recurrence of ovarian tumor. In contrast, WFA
if employed alone or in combination with CIS ameliorates this
unwanted effect. The data obtained from our study suggest that
WFA alone or in combination with CIS may serve as a safer and
more efficacious therapy for both first line and second line options
for ovarian cancer.
Acknowledgments
We thank Renu Kakar for expert technical assistance.
Author Contributions
Conceived and designed the experiments: SSK. Performed the experi-
ments: SSK SKS KSP. Analyzed the data: SKS. Wrote the paper: SSK.
Contributed reagents/material/planning of experiments: SKB. Edited the
manuscript: MZR. Provided input in planning the experiments: DMM.
Histopathological analysis of tumors and normal tissues MM.
References
1. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics. CA Cancer J Clin
63: 11–30.
2. Hunn J, Rodriguez GC (2012) Ovarian cancer: etiology, risk factors, and
epidemiology. Clin Obstet Gynecol 55: 3–24.
3. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines
in Oncology. Ovarian Cancer. Version 1.2013. Available: HTTP://www.nccn.
org/professionals/physician_gls/pdf/ovarian.pdf
4. Piccart MJ, Bertelsen K, Stuart G, Cassidy J, Mangioni C, et al. (2003) Long-
term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen
over the cyclophosphamide-cisplatin combination in advanced ovarian cancer.
Int J Gynecol Cancer 13 Suppl 2: 144–148.
5. Matsuo K, Lin YG, Roman LD, Sood AK (2010) Overcoming platinum
resistance in ovarian carcinoma. Expert Opin Investig Drugs 19: 1339–1354.
Figure 8. Western blot analysis of Notch1, Hes1 and Hey 1
proteins from tumors collected from mock treated mice and
mice treated with WFA and CIS both alone and in combination.
Beta-actin was used as an internal control. The data shown is
representative of two independent experiments. Con = control, W =
WFA. Values shown in parenthesis are mg/kg.
doi:10.1371/journal.pone.0107596.g008
WFA and Cisplatin Target Ovarian Cancer Stem Cells
PLOS ONE | www.plosone.org 7 September 2014 | Volume 9 | Issue 9 | e107596
6. Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, et al. (2012) Molecular
mechanisms of cisplatin resistance. Oncogene 31: 1869–1883.
7. El-Awady SE, Moustafa YM, Abo-Elmatty DM, Radwan A (2011) Cisplatin-
induced cardiotoxicity: Mechanisms and cardioprotective strategies. Eur J Phar-
macol 650: 335–41.
8. Kintzel PE (2001) Anticancer drug-induced kidney disorders. Drug Saf 24(1):
19–38.
9. Lieberthal W, Triaca V, Levine J (1996) Mechanisms of death induced by
cisplatin in proximal tubular epithelial cells: apoptosis vs. necrosis. Am J Physiol
270: F700–708.
10. Kakar SS, Jala VR, Fong MY (2012) Synergistic cytotoxic action of cisplatin and
withaferin A on ovarian cancer cell lines. Biochem Biophys Res Commun 423:
819–825.
11. Fugner A (1973) Inhibition of immunologically induced inflammation by the
plant steroid withaferin A. Arzneimittelforschung 23: 932–935.
12. Rasool M, Varalakshmi P (2006) Immunomodulatory role of Withania
somnifera root powder on experimental induced inflammation: An in vivo
and in vitro study. Vascul Pharmacol 44: 406–410.
13. Scartezzini P, Speroni E (2000) Review on some plants of Indian traditional
medicine with antioxidant activity. J Ethnopharmacol 71: 23–43.
14. Gupta SK, Mohanty I, Talwar KK, Dinda A, Joshi S, et al. (2004)
Cardioprotection from ischemia and reperfusion injury by Withania somnifera:
a hemodynamic, biochemical and histopathological assessment. Mol Cell
Biochem 260: 39–47.
15. Stan SD, Hahm ER, Warin R, Singh SV (2008) Withaferin A causes FOXO3a-
and Bim-dependent apoptosis and inhibits growth of human breast cancer cells
in vivo. Cancer Res 68: 7661–7669.
16. Mohan R, Hammers HJ, Bargagna-Mohan P, Zhan XH, Herbstritt CJ, et al.
(2004) Withaferin A is a potent inhibitor of angiogenesis. Angiogenesis 7: 115–
122.
17. Srinivasan S, Ranga RS, Burikhanov R, Han SS, Chendil D (2007) Par-4-
dependent apoptosis by the dietary compound withaferin A in prostate cancer
cells. Cancer Res 67: 246–253.
18. Stan SD, Zeng Y, Singh SV (2008) Ayurvedic medicine constituent withaferin a
causes G2 and M phase cell cycle arrest in human breast cancer cells. Nutr
Cancer 60 Suppl 1: 51–60.
19. Munagala R, Kausar H, Munjal C, Gupta RC (2011) Withaferin A induces p53-
dependent apoptosis by repression of HPV oncogenes and upregulation of tumor
suppressor proteins in human cervical cancer cells. Carcinogenesis 32: 1697–
16705.
20. Yu Y, Hamza A, Zhang T, Gu M, Zou P, et al. (2010) Withaferin A targets heat
shock protein 90 in pancreatic cancer cells. Biochem Pharmacol 79: 542–551.
21. Mayola E, Gallerne C, Esposti DD, Martel C, Pervaiz S, et al. (2011) Withaferin
A induces apoptosis in human melanoma cells through generation of reactive
oxygen species and down-regulation of Bcl-2. Apoptosis 16: 1014–1027.
22. Choi MJ, Park EJ, Min KJ, Park JW, Kwon TK (2011) Endoplasmic reticulum
stress mediates withaferin A induced apoptosis in human renal carcinoma cells.
Toxicol In Vitro 25: 692–698.
23. Samadi AK, Mukerji R, Shah A, Timmermann BN, Cohen MS (2010) A novel
RET inhibitor with potent efficacy against medullary thyroid cancer in vivo.
Surgery 148: 1228–1236.
24. Samadi AK, Tong X, Mukerji R, Zhang H, Timmermann BN, et al. (2010)
Withaferin A, a cytotoxic steroid from Vassobia breviflora, induces apoptosis in
human head and neck squamous cell carcinoma. J Nat Prod 73: 1476–1481.
25. Shah N, Kataria H, Kaul SC, Ishii T, Kaur G, et al. (2009) Effect of the
alcoholic extract of Ashwagandha leaves and its components on proliferation,
migration, and differentiation of glioblastoma cells: combinational approach for
enhanced differentiation. Cancer Sci 100: 1740–1747.
26. Oh JH, Lee TJ, Kim SH, Choi YH, Lee SH, et al. (2008) Induction of apoptosis
by withaferin A in human leukemia U937 cells through down-regulation of Akt
phosphorylation. Apoptosis 13: 1494–1504.
27. Oh JH, Kwon TK (2009) Withaferin A inhibits tumor necrosis factor-alpha-
induced expression of cell adhesion molecules by inactivation of Akt and NF-
kappaB in human pulmonary epithelial cells. Int Immunopharmacol 9: 614–
619.
28. Mayola E, Gallerne C, Esposti DD, Martel C, Pervaiz S, et al. (2011) Withaferin
A induces apoptosis in human melanoma cells through generation of reactive
oxygen species and down-regulation of Bcl-2. Apoptosis 16: 1014–27.
29. Roy RV, Suman S, Das TP, Luevano JE, Damodaran C (2013) Withaferin A, a
steroidal lactone from Withania somnifera, induces mitotic catastrophe and
growth arrest in prostate cancer cells. J Nat Prod 76: 1909–1915.
30. Malik F, Kumar A, Bhushan S, Khan S, Bhatia A, et al. (2007) Reactive oxygen
species generation and mitochondrial dysfunction in the apoptotic cell death of
human myeloid leukemia HL-60 cells by a dietary compound withaferin A with
concomitant protection by N-acetyl cysteine. Apoptosis 12: 2115–2133.
31. Lee TJ, Um HJ, Min do S, Park JW, Choi KS, et al. (2009) Withaferin A
sensitizes TRAIL-induced apoptosis through reactive oxygen species-mediated
up-regulation of death receptor 5 and downregulation of c-FLIP. Free Radic
Biol Med 46: 1639–1649.
32. Hahm ER, Moura MB, Kelley EE, Van Houten B, Shiva S, et al. (2011)
Withaferin a-induced apoptosis in human breast cancer cells is mediated by
reactive oxygen species. PLoS One 6: e23354.
33. Koduru S, Kumar R, Srinivasan S, Evers MB, Damodaran C (2010) Notch-1
inhibition by Withaferin-A: a therapeutic target against colon carcinogenesis.
Mol Cancer Ther 9: 202–210.
34. Hermann PC, Huber SL, Heeschen C (2008) Metastatic cancer stem cells: a new
target for anti-cancer therapy? Cell Cycle 7: 188–193.
35. Dean M, Fojo T, Bates S (2005) Tumour stem cells and drug resistance. Nat Rev
Cancer 5: 275–284.
36. Bonnet D, Dick JE (1997) Human acute myeloid leukemia is organized as a
hierarchy that originates from a primitive hematopoietic cell. Nat Med 3: 730–
737.
37. Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, et al. (1994) A cell
initiating human acute myeloid leukemia after transplantation into SCID mice.
Nature 367: 645–648.
38. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003)
Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad
Sci U S A 100: 3983–3988.
39. Medema JP (2013) Cancer stem cells: the challenges ahead. Nat Cell Biol 15:
338–344.
40. Chen L, Kasai T, Li Y, Sugii Y, Jin G, et al. (2012) A model of cancer stem cells
derived from mouse induced pluripotent stem cells. PLoS One 7: e33544.
41. Driessens G, Beck B, Caauwe A, Simons BD, Blanpain C (2012) Defining the
mode of tumour growth by clonal analysis. Nature 488: 527–530.
42. Schepers AG, Snippert HJ, Stange DE, van den Born M, van Es JH, et al. (2012)
Lineage tracing reveals Lgr5+ stem cell activity in mouse intestinal adenomas.
Science 337(6095): 730–735.
43. Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM, et al. (2008)
Efficient tumour formation by single human melanoma cells. Nature 456: 593–
598.
44. Dalerba P, Cho RW, Clarke MF (2007) Cancer stem cells: models and concepts.
Annu Rev Med 58: 267–284.
45. Bapat SA, Mali AM, Koppikar CB, Kurrey NK (2005) Stem and progenitor-like
cells contribute to the aggressive behavior of human epithelial ovarian cancer.
Cancer Res 65: 3025–3029.
46. Kurrey NK, Amit K, Bapat SA (2005) Snail and Slug are major determinants of
ovarian cancer invasiveness at the transcription level. Gyne Oncol 97: 155–165.
47. Zhang S, Balch C, Chan MW, Lai HC, Matei D, et al. (2008) Identification and
characterization of ovarian cancer-initiating cells from primary human tumors,
Cancer Res 68: 4311–4320.
48. Deng S, Yang X, Lassus H, Liang S, Kaur S, et al. (2010) Distinct expression
levels and patterns of stem cell marker, aldehyde dehydrogenase isoform 1
(ALDH1), in human epithelial cancers. PLoS ONE 5: e10277.
49. Silva IA, Bai S, McLean K, Yang K, Griffith K, et al. (2011) Aldehyde
dehydrogenase and CD133 define angiogenic ovarian cancer stem cells that
portend poor patient survival, Cancer Res 71: 3991–4001.
50. Dyall S, Gayther SA, Dafou D (2010) Cancer stem cells and epithelial ovarian
cancer. J Oncol 2010: 105269.
51. Alvero AB, Chen R, Fu HH, Montagna M, Schwartz PE, et al. (2009) Molecular
phenotyping of human ovarian cancer stem cells unravels the mechanisms for
repair and chemoresistance. Cell Cycle 8: 158–166.
52. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, et al. (2006) Cancer
stem cells–perspectives on current status and future directions: AACR Workshop
on cancer stem cells. Cancer Res 66: 9339–9344.
53. Abubaker K, Latifi A, Luwor R, Nazaretian S, Zhu H, et al. (2013) Short-term
single treatment of chemotherapy results in the enrichment of ovarian cancer
stem cell like cells leading to an increased tumor burden. Mol Cancer 12: 24.
54. Malik MT, Kakar SS (2006) Regulation of angiogenesis and invasion by human
Pituitary tumor transforming gene (PTTG) through increased expression and
secretion of matrix metalloproteinase-2 (MMP-2). Mol Cancer 5: 61.
55. Nunez-Cruz S, Connolly DC, Scholler N (2010) An orthotopic model of serous
ovarian cancer in immunocompetent mice for in vivo tumor imaging and
monitoring of tumor immune responses. J Vis Exp 28.pii: 2146.
56. Fong MY, Jin S, Rane M, Singh RK, Gupta R, et al. (2012) Withaferin A
synergizes the therapeutic effect of doxorubicin through ROS-mediated
autophagy in ovarian cancer. PLoS One 7: e42265.
57. Tomao F, Papa A, Strudel M, Rossi L, Lo Russo G, et al. (2014) Investigating
Molecular Profiles of Ovarian Cancer: An Update on Cancer Stem Cells.
J Cancer 5: 301–310.
58. Ramdass B, Duggal R, Minev B, Chowdhary A, Koka P (2013) Functional role
of solid tumor stem cells in disease etiology and susceptibility to therapeutic
interventions. J Stem Cells 8: 189–231.
59. Ponnusamy MP, Batra SK (2008) Ovarian cancer: emerging concept on cancer
stem cells. J Ovarian Res, 1: 4.
60. Alvero AB, Fu HH, Holmberg J, Visintin I, Mor L, et al. (2009) Stem like
ovarian cancer cells can serve as tumor vascular progenitors. Stem Cells 7:
2405–2413.
61. Reya T, Clevers H (2005) Wnt signaling in stem cells and cancer. Nature 434:
843
62. Liu S, Dontu G, Mantle ID, Patel S, Ahn NS, et al. (2006) Hedgehogsignaling
and Bmi-1 regulate self-renewal of normal and malignant human mammary
stem cells. Cancer Res 66: 6063–6071.
63. Dontu G, Jackson KW, McNicholas E, Kawamura MJ, Abdallah WM, et al.
(2004) Role of Notch signaling in cell-fate determination of human mammary
stem/progenitor cells, Breast Cancer Res 6: 605–615.
WFA and Cisplatin Target Ovarian Cancer Stem Cells
PLOS ONE | www.plosone.org 8 September 2014 | Volume 9 | Issue 9 | e107596
64. Giles RH, van Es JH, Clevers H (2003) Caught up in a Wnt storm: wnt signaling
in cancer, Biochim Biophys Acta 1653: 1–24.
65. Mimeault M, Batra SK (2012) Novel biomarkers and therapeutic targets for
optimizing the therapeutic management of melanomas. World J Clin Oncol 3:
32–42.
66. Wu KJ, Yang MH (2011) Epithelial-mesenchymal transition and cancer
stemness: the Twist1-Bmi1connection. Biosci Rep 31: 449–455.
67. Jain P, Alahari SK (2011) Breast cancer stem cells: a new challenge for breast
cancer treatment. Front Biosci 16: 1824–1832.
68. Suman S, Das TP, Damodaran C (2013) Silencing NOTCH signaling causes
growth arrest in both breast cancer stem cells and breast cancer cells.
Br J Cancer, 109: 2587–2596.
69. Shi W, Harris AL (2006) Notch signaling in breast cancer and tumor
angiogenesis: cross-talk and therapeutic potentials. J Mammary Gland Biol
Neoplasia 11: 41–52.
70. Gangopadhyay S, Nandy A, Hor P, Mukhopadhyay A (2013) Breast cancer stem
cells: a novel therapeutic target. Clin Breast Cancer 13: 7–15.
71. Lengyel E (2010) Ovarian cancer development and metastasis. Am J Pathol 177:
1053–1064.
72. Christen RD, Isonishi S, Jones JA, Jekunen AP, Hom DK, et al. (1994) Signaling
and drug sensitivity. Cancer Metastasis Rev 13: 175–189.
73. Brown R, Clugston C, Burns P, Edlin A, Vasey P, et al. (1993) Increased
accumulation of p53 protein in cisplatin-resistant ovarian cell lines. Int J Cancer
55: 678–684.
74. Perego P, Giarola M, Righetti SC, Supino R, Caserini C, et al. (1996)
Association between cisplatin resistance and mutation of p53 gene and reduced
bax expression in ovarian carcinoma cell systems. Cancer Res 56: 556–62.
75. Hollier BG, Evans K, Mani SA (2009) The epithelial-to-mesenchymal transition
and cancer stem cells: a coalition against cancer therapies. J Mammary Gland
Biol Neoplasia 14: 29–43.
76. Ahmed N, Abubaker K, Findlay J, Quinn M (2010) Epithelial mesenchymal
transition and cancer stem cell-like phenotypes facilitate chemoresistance in
recurrent ovarian cancer. Curr Cancer Drug Targets 10: 268–278.
77. Latifi A, Luwor RB, Bilandzic M, Nazaretian S, Stenvers K, et al. (2012)
Isolation and characterization of tumor cells from the ascites of ovarian cancer
patients: molecular phenotype of chemoresistant ovarian tumors. PLoS One 7:
e46858.
78. Gao MQ, Choi YP, Kang S, Youn JH, Cho NH (2010) CD24+ cells from
hierarchically organized ovarian cancer are enriched in cancer stem cells.
Oncogene 29: 2672–2680.
79. Landen CN Jr, Goodman B, Katre AA, Steg AD, Nick AM, et al. (2010)
Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer. Mol
Cancer Ther 9: 3186–3199.
80. Guo X, Xiong L, Sun T, Peng R, Zou L, et al. (2012) Expression features of
SOX9 associate with tumor progression and poor prognosis of hepatocellular
carcinoma. Diagn Pathol 7: 44.
81. Surowiak P, Materna V, Maciejczyk A, Kaplenko I, Spaczynski M, et al. (2006)
CD46 expression is indicative of shorter revival-free survival for ovarian cancer
patients. Anticancer Res 26: 4943–4948.
82. Oh DH, Kim SH, Jung S, Sung YK, Bang SY, et al. (2011) Precuneus
hypoperfusion plays an important role in memory impairment of patients with
systemic lupus erythematosus. Lupus 20: 855–860.
83. Steg AD, Bevis KS, Katre AA, Ziebarth A, Dobbin ZC, et al. (2012) Stem cell
pathways contribute to clinical chemoresistance in ovarian cancer. Clin Cancer
Res 18: 869–881.
84. Szotek PP, Pieretti-Vanmarcke R, Masiakos PT, Dinulescu DM, Connolly D,
et al. (2006) Ovarian cancer side population defines cells with stem cell-like
characteristics and Mullerian Inhibiting Substance responsiveness. Proc Natl
Acad Sci U S A 103: 11154–11159.
85. Vathipadiekal V, Saxena D, Mok SC, Hauschka PV, Ozbun L, et al. (2012)
Identification of a potential ovarian cancer stem cell gene expression profile from
advanced stage papillary serous ovarian cancer. PLoS One 7: e29079.
86. Kwon MJ, Shin YK (2013) Regulation of ovarian cancer stem cells or tumor-
initiating cells. Int J Mol Sci 14: 6624–6648.
WFA and Cisplatin Target Ovarian Cancer Stem Cells
PLOS ONE | www.plosone.org 9 September 2014 | Volume 9 | Issue 9 | e107596
